

# Joshua J Gagne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/204945/publications.pdf>

Version: 2024-02-01

200  
papers

5,104  
citations

136950

32  
h-index

123424

61  
g-index

204  
all docs

204  
docs citations

204  
times ranked

6280  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. <i>JAMA Network Open</i> , 2022, 5, e220194.	5.9	7
2	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1051.	7.4	14
3	Type of Oral Anticoagulant and Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for VTE—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 79.	7.4	0
4	Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021, 128, 248-255.	5.2	4
5	Drug–Drug Interaction Surveillance Study: Comparing Self–Controlled Designs in Five Empirical Examples in Real–World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1353-1360.	4.7	4
6	Empirical assessment of case–based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (<scp>SNDS</scp>). <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 320-333.	1.9	3
7	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. <i>Drug Safety</i> , 2021, 44, 327-335.	3.2	4
8	A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics. <i>American Journal of Epidemiology</i> , 2021, 190, 1424-1433.	3.4	8
9	Trends in Medicare Part D Inhaler Spending: 2012–2018. <i>Annals of the American Thoracic Society</i> , 2021, 18, 548-550.	3.2	8
10	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. <i>American Heart Journal</i> , 2021, 233, 109-121.	2.7	23
11	Control yourself: <scp>ISPE–endorsed</scp> guidance in the application of <scp>self–controlled</scp> study designs in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 671-684.	1.9	36
12	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. <i>Drug Safety</i> , 2021, 44, 743-751.	3.2	7
13	Association of California’s Prescription Drug Coupon Ban With Generic Drug Use. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2399.	7.4	2
14	Estimating Rebates and Other Discounts Received by Medicare Part D. <i>JAMA Health Forum</i> , 2021, 2, e210626.	2.2	18
15	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. <i>Value in Health</i> , 2021, 24, 804-811.	0.3	8
16	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1011-1017.	4.7	16
17	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1214-1223.	3.9	48
18	COPD EXACERBATIONS AND PNEUMONIA HOSPITALIZATIONS IN NEW USERS OF COMBINATION MAINTENANCE INHALERS: A COMPARATIVE EFFECTIVENESS AND SAFETY STUDY. <i>Chest</i> , 2021, 160, A1795.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 757-769.	1.9	8
20	Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example. <i>Value in Health</i> , 2020, 23, 217-226.	0.3	6
21	Response to "The Self-Controlled Case Series Design as a Viable Alternative to Studying Clinically Relevant Drug Interactions". <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 323-323.	4.7	1
22	Validation of a comorbidity index for use in obstetric patients: A nationwide cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 399-405.	2.8	14
23	Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1334-1342.	4.7	2
24	Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 87.	7.4	9
25	Exact sequential analysis for multiple weighted binomial end points. <i>Statistics in Medicine</i> , 2020, 39, 340-351.	1.6	1
26	Differences in characteristics of Medicare patients treated by ophthalmologists and optometrists. <i>PLoS ONE</i> , 2020, 15, e0227783.	2.5	7
27	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. <i>Epidemiology</i> , 2020, 31, 806-814.	2.7	6
28	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. <i>Annals of Internal Medicine</i> , 2020, 172, 463.	3.9	72
29	Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. <i>JAMA Internal Medicine</i> , 2020, 180, 1596.	5.1	48
30	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020, 80, 1961-1972.	10.9	24
31	Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations. <i>Scientific Reports</i> , 2020, 10, 10070.	3.3	6
32	Bias in case-crossover studies of medications due to persistent use: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1079-1085.	1.9	10
33	Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (<scp>SNDS</scp>). <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 890-903.	1.9	5
34	Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018. <i>Drug Safety</i> , 2020, 43, 669-675.	3.2	14
35	Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 993-1000.	1.9	6
36	Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation. <i>American Journal of Epidemiology</i> , 2020, 189, 1467-1477.	3.4	3

#	ARTICLE	IF	CITATIONS
37	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. <i>American Heart Journal</i> , 2020, 228, 36-43.	2.7	11
38	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. <i>Cardiovascular Diabetology</i> , 2020, 19, 25.	6.8	16
39	Improving measurement of binary covariates in claims data: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1093-1100.	1.9	1
40	Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications. <i>Value in Health</i> , 2020, 23, 434-440.	0.3	6
41	Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019. <i>JAMA Internal Medicine</i> , 2020, 180, 1006.	5.1	9
42	Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists. <i>American Journal of Managed Care</i> , 2020, 26, 340-347.	1.1	2
43	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. <i>Drug Safety</i> , 2019, 42, 85-93.	3.2	5
44	Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1156-1163.	4.7	22
45	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. <i>Drug Safety</i> , 2019, 42, 1355-1363.	3.2	1
46	Association of Opioid Overdose With Opioid Prescriptions to Family Members. <i>JAMA Internal Medicine</i> , 2019, 179, 1186.	5.1	72
47	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate "Real World" Evidence of Comparative Effectiveness and Safety. <i>Drug Safety</i> , 2019, 42, 1297-1309.	3.2	13
48	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 238-244.	4.7	17
49	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 374.	7.4	31
50	Role of Authorized Generics in Postapproval Surveillance of Generic Drug Products. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 313-315.	4.7	3
51	Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1513-1521.	4.7	10
52	Evaluation of Use of Technologies to Facilitate Medical Chart Review. <i>Drug Safety</i> , 2019, 42, 1071-1080.	3.2	3
53	Errors in Exclusion of Data and Reported Trends of Prescriptions in Study of Opioid Prescriptions Dispensed to Children and Adolescents. <i>JAMA Pediatrics</i> , 2019, 173, 697.	6.2	1
54	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1142.	4.1	51

#	ARTICLE	IF	CITATIONS
55	Using Healthcare Databases to Refine Understanding of Exploratory Associations Between Drugs and Progression of Open-Angle Glaucoma. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 874-883.	4.7	13
56	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—A plasmode simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 879-886.	1.9	4
57	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 671-679.	1.9	5
58	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. <i>PLoS Medicine</i> , 2019, 16, e1002763.	8.4	55
59	Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 665-670.	1.9	10
60	Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. <i>Journals of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 113-121.	0.9	12
61	Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1037-1042.	4.4	14
62	Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017. <i>JAMA Pediatrics</i> , 2019, 173, 98.	6.2	21
63	A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. <i>Journal of General Internal Medicine</i> , 2019, 34, 420-428.	2.6	8
64	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. <i>Patient</i> , 2019, 12, 235-246.	2.7	6
65	Days' Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting — United States, 2014. <i>Morbidity and Mortality Weekly Report</i> , 2019, 68, 140-143.	15.1	23
66	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 707-712.	1.9	7
67	Trends and Patterns of Corticosteroid Use During Coronary Artery Bypass Grafting Surgery in the United States. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 226-236.	2.0	0
68	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. <i>Cancer</i> , 2018, 124, 2205-2211.	4.1	6
69	Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 383-390.	1.9	2
70	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1008-1015.	4.7	3
71	Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. <i>Diabetes Care</i> , 2018, 41, 713-722.	8.6	26
72	Use of olmesartan and enteropathy outcomes: a multi-database study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 792-800.	3.7	22

#	ARTICLE	IF	CITATIONS
73	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 57-66.	1.4	2
74	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 263-271.	1.9	16
75	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. <i>BMJ: British Medical Journal</i> , 2018, 361, k1180.	2.3	27
76	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 567-569.	1.9	11
77	Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. <i>European Journal of Epidemiology</i> , 2018, 33, 545-555.	5.7	27
78	Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. <i>American Journal of Epidemiology</i> , 2018, 187, 1799-1807.	3.4	56
79	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and <i>Clostridium difficile</i> infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 731-739.	1.9	6
80	Can Patient Navigators Improve Adherence to Disease-Modifying Antirheumatic Drugs? Quantitative Findings From a Six-Month Single-Arm Pilot Intervention. <i>Arthritis Care and Research</i> , 2018, 70, 1400-1405.	3.4	7
81	Patterns of opioid initiation at first visits for pain in United States primary care settings. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 495-503.	1.9	30
82	Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 30-37.	1.9	10
83	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1093-1099.	4.7	13
84	What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. <i>Journal of Oncology Practice</i> , 2018, 14, 139-140.	2.5	1
85	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004632.	2.2	30
86	Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. <i>Epidemiology</i> , 2018, 29, 895-903.	2.7	34
87	Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10. <i>Medical Care</i> , 2018, 56, 812-812.	2.4	19
88	Identifying signals of interest when screening for drug-outcome associations in health care data. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1865-1867.	2.4	9
89	Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1073-1082.	1.4	1
90	A National Population-based Study of Adults With Coronary Artery Disease and Coarctation of the Aorta. <i>American Journal of Cardiology</i> , 2018, 122, 2120-2124.	1.6	20

#	ARTICLE	IF	CITATIONS
91	Impact of a Metoprolol Extended Release Shortage on Post-Myocardial Infarction $\beta$ -Blocker Utilization, Adherence, and Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004096.	2.2	1
92	Using Previous Medication Adherence to Predict Future Adherence. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1146-1155.	0.9	29
93	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1361-1370.	1.9	9
94	Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1061-1068.e1.	1.2	26
95	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. <i>Health Affairs</i> , 2018, 37, 125-133.	5.2	41
96	Assessing the impact of the new ICD-10-CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensin-converting enzyme inhibitors and angioedema. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 829-838.	1.9	6
97	Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs. <i>Drug Safety</i> , 2018, 41, 1313-1323.	3.2	12
98	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 872-877.	1.9	2
99	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. <i>JAMA Internal Medicine</i> , 2018, 178, 1182.	5.1	71
100	Opioid Overdose After Surgical Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 502.	7.4	37
101	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. <i>PLoS ONE</i> , 2018, 13, e0200886.	2.5	11
102	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004684.	2.2	6
103	Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. <i>American Journal of Epidemiology</i> , 2018, 187, 2439-2448.	3.4	8
104	Generating Evidence of Clinical Outcomes of Drug-Drug Interactions. <i>Drug Safety</i> , 2017, 40, 101-103.	3.2	14
105	Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 25-32.	1.4	13
106	New-user designs with conditional propensity scores: a unified complement to the traditional active comparator new-user approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 469-471.	1.9	3
107	Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. <i>Drugs</i> , 2017, 77, 427-433.	10.9	7
108	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 694-701.	1.9	8

#	ARTICLE	IF	CITATIONS
109	Strength of evidence for labeled dosing recommendations in renal impairment. <i>Clinical Trials</i> , 2017, 14, 219-221.	1.6	1
110	Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. <i>Drug Safety</i> , 2017, 40, 923-932.	3.2	11
111	Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 200-209.	1.4	16
112	The Potential Return on Public Investment in Detecting Adverse Drug Effects. <i>Medical Care</i> , 2017, 55, 545-551.	2.4	6
113	Evidence of potential bias in a comparison of $\beta_2$ blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. <i>BMJ Open</i> , 2017, 7, e012997.	1.9	6
114	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017, 20, 1009-1022.	0.3	70
115	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1507-1512.	1.9	15
116	Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 914-916.	4.7	7
117	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1018-1032.	1.9	126
118	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. <i>Medical Care</i> , 2017, 55, 1046-1051.	2.4	67
119	Sentinel Modular Program for Propensity Score-Matched Cohort Analyses. <i>Epidemiology</i> , 2017, 28, 838-846.	2.7	32
120	The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. <i>American Journal of Epidemiology</i> , 2017, 185, 842-852.	3.4	15
121	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. <i>Drug Safety</i> , 2017, 40, 91-100.	3.2	0
122	Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. <i>International Journal of Cardiology</i> , 2017, 228, 761-770.	1.7	21
123	Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 294-300.	1.9	39
124	Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. <i>American Journal of Cardiology</i> , 2017, 119, 651-657.	1.6	21
125	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. <i>European Journal of Cancer</i> , 2017, 70, 22-33.	2.8	28
126	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. <i>Drug Safety</i> , 2017, 40, 105-108.	3.2	9



#	ARTICLE	IF	CITATIONS
127	Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network. <i>Current Epidemiology Reports</i> , 2017, 4, 298-306.	2.4	16
128	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. <i>Annals of Internal Medicine</i> , 2017, 167, 845.	3.9	37
129	Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. <i>BioResearch Open Access</i> , 2017, 6, 159-168.	2.6	10
130	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1023-1032.	1.9	6
131	Balancing benefits and harms: privacy protection policies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 969-971.	1.9	1
132	Developing alerting thresholds for prospective drug safety monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 755-762.	1.9	0
133	Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 798-814.	1.9	8
134	Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 944-952.	1.9	5
135	Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. <i>JAMA Internal Medicine</i> , 2016, 176, 1317.	5.1	32
136	Identification of Associations Between Prescribed Medications and Cancer: A Nationwide Screening Study. <i>EBioMedicine</i> , 2016, 7, 73-79.	6.1	29
137	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. <i>Journal of Clinical Epidemiology</i> , 2016, 76, 200-208.	5.0	21
138	Comparison of Calipers for Matching on the Disease Risk Score. <i>American Journal of Epidemiology</i> , 2016, 183, 937-948.	3.4	11
139	Prevalence and Predictors of Generic Drug Skepticism Among Physicians. <i>JAMA Internal Medicine</i> , 2016, 176, 845.	5.1	43
140	Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. <i>Diabetes Research and Clinical Practice</i> , 2016, 115, 60-67.	2.8	6
141	Switching generic antiepileptic drug manufacturer not linked to seizures. <i>Neurology</i> , 2016, 87, 1796-1801.	1.1	35
142	Prescription Trends—Brand-Name Drugs vs Generic—Reply. <i>JAMA Internal Medicine</i> , 2016, 176, 1574.	5.1	0
143	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. <i>American Heart Journal</i> , 2016, 180, 90-97.	2.7	24
144	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. <i>Current Epidemiology Reports</i> , 2016, 3, 277-284.	2.4	10

#	ARTICLE	IF	CITATIONS
145	Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis. <i>BMJ Open</i> , 2016, 6, e010958.	1.9	4
146	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. <i>American Journal of Epidemiology</i> , 2016, 183, 949-957.	3.4	24
147	Time for integrating clinical, lifestyle and molecular data to predict drug responses – Authors' reply. <i>EBioMedicine</i> , 2016, 7, 11.	6.1	1
148	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. <i>Emerging Themes in Epidemiology</i> , 2016, 13, 5.	2.7	17
149	Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. <i>Journal of General Internal Medicine</i> , 2016, 31, 609-614.	2.6	53
150	Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 107-113.	5.0	40
151	Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. <i>PLoS ONE</i> , 2016, 11, e0163339.	2.5	8
152	A Unified Framework for Classification of Methods for Benefit-Risk Assessment. <i>Value in Health</i> , 2015, 18, 250-259.	0.3	16
153	Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. <i>Value in Health</i> , 2015, 18, 1063-1069.	0.3	3
154	Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. <i>Value in Health</i> , 2015, 18, 1057-1062.	0.3	3
155	Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. <i>Drug Safety</i> , 2015, 38, 849-853.	3.2	7
156	Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. <i>Drugs</i> , 2015, 75, 633-650.	10.9	8
157	Comparative effectiveness of generic versus brand-name antiepileptic medications. <i>Epilepsy and Behavior</i> , 2015, 52, 14-18.	1.7	38
158	Thiazolidinediones and Parkinson Disease: A Cohort Study. <i>American Journal of Epidemiology</i> , 2015, 182, 936-944.	3.4	31
159	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. <i>Drug Safety</i> , 2015, 38, 1075-1082.	3.2	10
160	Common Models, Different Approaches. <i>Drug Safety</i> , 2015, 38, 683-686.	3.2	11
161	Restrictive Reimbursement Policies: Bias Implications for Claims-Based Drug Safety Studies. <i>Drug Safety</i> , 2014, 37, 771-776.	3.2	5
162	Ensuring Patient Privacy in Data Sharing for Postapproval Research. <i>New England Journal of Medicine</i> , 2014, 371, 1644-1649.	27.0	19

#	ARTICLE	IF	CITATIONS
163	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 619-627.	1.9	21
164	Patients' Preferences in Anticoagulant Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 912-919.	2.2	28
165	Cigarette Purchases at Pharmacies by Patients at High Risk of Smoking-Related Illness. <i>JAMA Internal Medicine</i> , 2014, 174, 2031.	5.1	6
166	Finding Meaningful Patterns in Adverse Drug Event Reports. <i>JAMA Internal Medicine</i> , 2014, 174, 1934.	5.1	11
167	Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel. <i>Drug Safety</i> , 2014, 37, 151-161.	3.2	15
168	SMART Designs in Observational Studies of Opioid Therapy Duration. <i>Journal of General Internal Medicine</i> , 2014, 29, 429-431.	2.6	2
169	"First-Wave" Bias When Conducting Active Safety Monitoring of Newly Marketed Medications with Outcome-Indexed Self-Controlled Designs. <i>American Journal of Epidemiology</i> , 2014, 180, 636-644.	3.4	18
170	Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. <i>Annals of Internal Medicine</i> , 2014, 161, 400.	3.9	137
171	Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1160-1167.	1.9	15
172	Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research. <i>Value in Health</i> , 2013, 16, 1054-1062.	0.3	28
173	Adjuvant vancomycin for antibiotic prophylaxis and risk of <i>Clostridium difficile</i> infection after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 472-478.	0.8	13
174	Statins and colorectal cancer risk: a longitudinal study. <i>Cancer Causes and Control</i> , 2013, 24, 777-782.	1.8	17
175	Development of a Comorbidity Index for Use in Obstetric Patients. <i>Obstetrics and Gynecology</i> , 2013, 122, 957-965.	2.4	325
176	Case-crossover Studies of Therapeutics. <i>Epidemiology</i> , 2013, 24, 375-378.	2.7	23
177	Comment on "Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership". <i>Statistics in Medicine</i> , 2013, 32, 1073-1074.	1.6	3
178	On analyzing therapeutic ineffectiveness reports. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 207-208.	1.9	1
179	Patterns and Predictors of Generic Narrow Therapeutic Index Drug Use Among Older Adults. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1586-1591.	2.6	19
180	Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 542-550.	1.9	66

#	ARTICLE	IF	CITATIONS
181	Disease risk score as a confounder summary method: systematic review and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 122-129.	1.9	44
182	Comment: Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies. <i>Annals of Pharmacotherapy</i> , 2012, 46, 303-304.	1.9	1
183	Comparative Effectiveness of Preventative Therapy for Venous Thromboembolism After Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 590-596.	3.9	32
184	Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. <i>Drug Safety</i> , 2012, 35, 407-416.	3.2	12
185	Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 480-486.	2.2	128
186	An Event-Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 631-639.	1.9	10
187	A combined comorbidity score predicted mortality in elderly patients better than existing scores. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 749-759.	5.0	728
188	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. <i>American Journal of Epidemiology</i> , 2011, 174, 1213-1222.	3.4	205
189	How Many "Me-Too" Drugs Is Too Many?. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 711.	7.4	61
190	Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1786.	7.4	62
191	Confounder summary scores when comparing the effects of multiple drug exposures. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 2-9.	1.9	47
192	Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs. <i>Drugs</i> , 2010, 70, 605-621.	10.9	164
193	Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 259-268.	1.9	27
194	Health Advisories and Patterns of Patient Monitoring Among New Users of Antidepressant Medications. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 590-594.	1.4	0
195	Concern still warranted: medication burden and persistence with lipid-lowering drugs. <i>American Journal of Managed Care</i> , 2009, 15, 74-5.	1.1	0
196	Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1125-1132.	1.9	108
197	Assessing Quality of Care for Migraineurs: A Model Health Plan Measurement Set. <i>Population Health Management</i> , 2008, 11, 203-208.	1.7	3
198	Candidemia in the in-patient setting: treatment options and economics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1643-1650.	1.8	25

#	ARTICLE	IF	CITATIONS
199	Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials. <i>Journal of Occupational and Environmental Medicine</i> , 2007, 49, 252-257.	1.7	13
200	Quality of Care Measures for Migraine: A Comprehensive Review. <i>Disease Management: DM</i> , 2007, 10, 138-146.	1.0	10